



APRECIA – The 3DP Pharmaceutical Company

Since 2004, Aprecia has been pioneering the technology of 3-Dimensional Printing (3DP) for pharmaceutical formulation and manufacturing. Aprecia manufactures SPRITAM® (levetiracetam) which is the world's first and only FDA-approved and marketed 3D-printed medication. The company continues to advance its capabilities to deliver novel drug dosage and delivery platforms to address significant unmet patient needs.

ZipDose® Technology is Aprecia's first proprietary platform that enables the production of high dose, fast-melt tablets designed for ease of swallowing with just a sip of liquid, as utilized in [Spritam®](#) (levetiracetam). ZipDose® can be used to create rapidly disintegrating oral dosage forms with features such as:

- Delivering ultra-low or high drug loads – even for doses beyond 1,000mg of active pharmaceutical ingredient – an unprecedented range for any other fast melt technology available today
- Ease of swallowing & administration with no liquid measuring required
- Diverse patient compliance benefits such as taste masking and modified release capabilities via engineered and coated particles

WHY 3DP?

APRECIA's additive and compression-free manufacturing approach enables the flexibility, precision, & freedom to design unique, patient-centric medications unachievable through traditional methods. 3DP unlocks the future of pharmaceutical manufacturing.

Aprecia specializes in using 3DP to address complex formulation barriers. Our platform enables rapid prototyping and adaptive clinical studies leveraging on-demand production ability. Beyond ZipDose®, Aprecia can deliver a range of solutions including ultra-low dose, modified release, and combination therapies at various production scales from ultra-orphan to large therapeutic categories.

Aprecia is in late stage planning for new products leveraging ZipDose® and new technology platforms in the coming years. Aprecia seeks to partner with innovative pharmaceutical companies to bring unique solutions and capabilities to their current product assets and research pipelines.



APRECIA FACTS

- ❖ Privately held and established in 2004
- ❖ Headquartered in Blue Ash, Ohio with 190,000-sq.ft. FDA approved manufacturing facility
- ❖ Research & Development Center in East Windsor, New Jersey
- ❖ Validated process through product approval
- ❖ Feasibility demonstrated for over 50 different drug formulations
- ❖ Rapid prototyping capability
- ❖ Product development and manufacturing expertise & capabilities from concept to commercialization
- ❖ IP protected platform beyond 2030